非小细胞肺癌骨寡转移立体定向放疗:欧洲多中心队列结局
该欧洲15中心回顾性队列纳入2010–2024年接受骨寡转移(<5处)SBRT的85例NSCLC患者(111处病灶),中位随访14个月,2年局部无复发生存87.2%,单发骨寡转移者PFS优于2–3处者,病灶较大和数目增多与OS、PFS不良相关,治疗耐受良好。
要点
- 骨寡转移SBRT的2年局部无复发生存为87.2%。
- 单发骨寡转移者1年PFS为60.1%,2–3处者为10.2%。
- 病灶较大及数目增多与OS、PFS不良相关。
核心结论
- NSCLC骨寡转移SBRT似乎有效且耐受良好。
- 单发骨寡转移是有利预后因素。
- 需前瞻性研究确认并明确SBRT在多学科管理中的作用。
研究设计与样本
- 回顾性分析2010–2024年15个欧洲癌症中心接受SBRT的NSCLC骨寡转移患者。
- 纳入标准为骨寡转移<5处,共85例患者、111处治疗病灶。
- 中位随访14个月(IQR 7–24个月)。
主要发现
- 2年局部无复发生存(FFLR)为87.2%(95%CI 73.3%–94.1%)。
- 单发骨寡转移1年PFS为60.1%(95%CI 44.6%–72.5%),2年PFS为39.9%(95%CI 24.6%–54.8%)。
- 2–3处骨寡转移1年PFS为10.2%(95%CI 0.6%–35.8%),2年PFS为0%。
- 多变量分析中,较大骨寡转移与OS(HR 1.003;p<0.01)和PFS(HR 1.005;p<0.001)不良相关。
- 多变量分析中,治疗骨寡转移数目增多与OS(HR 1.72;p=0.03)和PFS(HR 1.93;p<0.01)不良相关。
关键数值与推荐
- 骨寡转移SBRT后骨折率为5.4%。
- 未观察到4级和5级不良事件。
- 2–3处骨寡转移者2年PFS为0%。
临床怎么用
- 对NSCLC单发骨寡转移可考虑SBRT,局部控制良好且耐受性佳。
- 骨寡转移数目较多或病灶较大者预后较差,选择SBRT需权衡获益。
局限性
- 回顾性设计、样本量较小(85例),随访时间有限。
- 2–3处骨寡转移亚组例数少,PFS置信区间宽。
- 需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Metastasis-directed radiotherapy is of increasing importance in the multidisciplinary management of oligometastatic non-small cell lung cancer (NSCLC), but outcome patterns for stereotactic body radiotherapy (SBRT) of bone oligometastases (BoM) remain insufficiently defined. We aimed to determine oncological outcomes and prognostic factors of SBRT for BoM of NSCLC. MATERIALS AND METHODS: Patients with NSCLC treated with SBRT for < 5 BoM between 2010 and 2024 at 15 European cancer centers were retrospectively analyzed. Outcomes included freedom from local recurrence (FFLR), progression-free survival (PFS), overall survival (OS), and adverse events. RESULTS: With a median follow-up of 14 months (IQR: 7-24 months), 85 patients with 111 treated BoM were analyzed. The 2-year FFLR was 87.2% (95%-CI: 73.3%-94.1%). The 1-/2-year PFS for singular BoM was 60.1% (CI: 44.6%-72.5%)/ 39.9% (CI: 24.6%-54.8%), while for 2-3 BoM they amounted to 10.2% (95%-CI: 0.6%-35.8%) and 0%. In multivariable analysis, less favorable outcome for OS and PFS was associated with larger BoM (HR 1.003; p < 0.01 and HR 1.005, p < 0.001) and increased number of treated BoM (HR 1.72; p = 0.03 and HR 1.93; p < 0.01). Treatment was well tolerated, with fracture rates of 5.4% and no grade 4 and 5 adverse events. CONCLUSION: This multicenter cohort analysis revealed that SBRT of BoM from NSCLC appears to be an effective and well-tolerated treatment. Presence of singular BoM was a favorable prognostic factor. Prospective studies are needed to confirm these findings and to determine the role of SBRT in the multidisciplinary management of oligometastases.
引用
- Schäfer S, Seiler I, Balermpas P, et al. Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort study. Radiat Oncol. 2026. PMID: 42157246. doi:10.1186/s13014-026-02855-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。